patient
immunodefici
type
autoimmun
diseas
reli
safe
therapi
intraven
immunoglobulin
ivig
manufactur
human
plasma
avail
sourc
therapeut
sinc
plasma
predispos
contamin
varieti
bloodborn
pathogen
ascertain
ensur
pathogen
safeti
plasmaderiv
therapeut
prioriti
among
manufactur
stateoftheart
manufactur
process
provid
high
safeti
standard
incorpor
viru
elimin
procedur
manufactur
process
base
mechan
procedur
group
three
class
partit
inactiv
virusfiltr
one
import
clinic
applic
intraven
immunoglobulin
ivig
suppli
broad
spectrum
antibodi
patient
antibodi
defici
throughout
live
patient
inherit
primari
antibodi
defici
treat
rel
high
dose
ivig
patient
develop
secondari
antibodi
defici
diseas
diseas
therapi
may
also
receiv
high
dose
ivig
long
period
time
sinc
ivig
first
develop
indic
found
benefit
high
dose
ivig
correct
immunolog
disord
autoimmun
diseas
origin
immunomodulatori
applic
induc
increas
platelet
level
patient
immun
thrombocytopen
purpura
itp
applic
discov
singl
multipl
cours
high
dose
ivig
success
use
treat
wide
varieti
autoimmun
disord
review
see
ref
sinc
regular
exposur
larg
quantiti
human
plasma
protein
carri
risk
infect
blood
born
pathogen
increas
pathogen
safeti
ivig
without
diminish
clinic
efficaci
high
prioriti
transmiss
homolog
serum
hepat
whole
blood
plasma
serum
great
concern
develop
plasma
fraction
procedur
produc
human
serum
albumin
world
war
ii
yellow
fever
vaccin
stabil
human
serum
produc
case
hepat
american
militari
personnel
epidemiolog
investig
strongli
suggest
pool
human
plasma
present
higher
risk
hepat
transmiss
whole
blood
attribut
increas
probabl
pool
plasma
would
contamin
one
sever
donor
sinc
plasma
pool
blood
donat
use
produc
albumin
effort
initi
inactiv
hepat
viru
human
serum
albumin
solut
gelli
cowork
report
hepat
transmiss
albumin
elimin
heat
h
c
procedur
possibl
discoveri
mm
acetyltryptophan
mm
sodium
capryl
increas
heat
resist
albumin
unfortun
plasma
protein
solut
inactiv
heat
earli
attempt
inactiv
virus
high
risk
product
unsuccess
accord
fda
high
risk
plasma
product
includ
fibrinogen
factor
viii
concentr
factor
ix
heat
albumin
solut
immunoglobulin
produc
cold
ethanol
fraction
consid
low
risk
product
percept
immunoglobulin
produc
cold
ethanol
fraction
low
risk
transmit
viru
infect
chang
lane
report
experiment
ivig
produc
cold
ethanol
fraction
transmit
nona
nonb
hepat
time
human
immunodefici
viru
isol
proven
transmiss
blood
blood
product
emerg
human
immunodefici
viru
hiv
report
nona
nonb
hepat
transmiss
ivig
product
other
caus
manufactur
regulatori
agenc
examin
exist
ivig
manufactur
process
capac
elimin
virus
develop
dedic
viru
inactiv
procedur
ivig
product
also
initi
studi
ivig
manufactur
procedur
suggest
cold
ethanol
fraction
remov
virus
two
mechan
inactiv
partit
sever
laboratori
demonstr
retrovirus
hiv
inactiv
cold
ethanol
condit
use
ivig
product
howev
vesicular
stomat
viru
vsv
sindbi
viru
sin
use
model
hepat
c
viru
hcv
stabl
similar
condit
year
sever
procedur
develop
prevent
pathogen
transmiss
increas
safeti
ivig
therapeut
protein
describ
procedur
includ
recent
technolog
term
virusfiltr
term
virusfiltr
becom
accept
nomenclatur
previous
call
nanofiltr
virusfiltr
remov
virus
regardless
presenc
absenc
lipid
envelop
also
elimin
pathogen
potenti
transmit
infect
virusfiltr
first
total
new
principl
pathogen
remov
incorpor
plasma
protein
manufactur
past
year
although
peopl
ill
alway
exclud
donat
blood
plasma
donor
feel
sick
clinic
symptom
even
though
infect
pathogen
window
period
blood
plasma
donat
may
transmit
pathogen
reason
donor
screen
test
develop
new
pathogen
also
sensit
therebi
reduc
window
period
review
bloodborn
pathogen
respect
relev
transfus
human
pathogen
caus
chronic
progress
wast
lethal
diseas
infecti
agent
preval
transfus
popul
consid
relev
use
criteria
hepat
b
viru
hbv
hcv
human
immunodefici
virus
type
character
relev
viru
formerli
name
parvoviru
cytomegaloviru
cmv
hepat
virus
hav
classifi
occasion
relev
sinc
review
publish
nonenvelop
virus
hav
becom
relev
new
virus
eg
west
nile
viru
sar
corona
viru
emerg
thu
relev
pathogen
transfus
evolv
concept
identif
hepat
virus
develop
sensit
donor
screen
test
becam
high
prioriti
earli
concern
hepat
transmiss
sensit
test
hbv
develop
use
elimin
infect
donor
unfortun
hbv
test
elimin
transfusionrel
hepat
search
one
nona
nonb
hepat
virus
initi
aid
epidem
led
rapid
develop
screen
test
antibodi
genom
nona
nonb
hepat
viru
isol
use
develop
donor
screen
test
hcv
today
plasma
screen
antibodi
syphili
hcv
hbv
extrem
sensit
test
hcv
hav
hbv
nucleic
acid
introduc
recent
use
reduc
window
period
plasma
fraction
class
protein
precipit
separ
protein
remain
solut
either
centrifug
filtrat
virus
frequent
precipit
along
protein
frozen
plasma
thaw
c
protein
call
cryoglobulin
remain
insolubl
fraction
call
cryoprecipit
contain
mani
protein
belong
coagul
cascad
eg
factor
viii
also
virus
tend
partit
cryoprecipit
virus
also
precipit
cold
ethanol
fibrinogen
fraction
cohnoncley
fraction
igg
fraction
cohnoncley
fraction
ii
iii
kistlernitschmann
precipit
see
fig
fig
distribut
model
virus
plasma
fraction
produc
cold
ethanol
precipit
illustr
tabl
viru
inactiv
capac
often
correl
log
reduct
factor
lrf
tabl
show
lrf
report
dedic
viru
inactiv
procedur
howev
inactiv
kinet
also
relev
rapid
inactiv
kinet
regard
evid
excess
capac
lengthi
inactiv
step
viru
still
detect
becom
nondetect
near
end
process
believ
provid
less
assur
viral
safeti
virus
compos
nucleic
acid
complex
protein
structur
unit
vari
complex
structur
unit
assembl
whole
infect
viru
held
togeth
noncoval
bond
envelop
virus
lipidbilay
membran
membran
associ
glycoprotein
nonenvelop
virus
frequent
small
stabl
icosahedr
particl
challeng
develop
viru
inactiv
procedur
protein
solut
inactiv
virus
without
harm
therapeut
protein
noncoval
bond
involv
viru
assembl
maintain
protein
nativ
biolog
activ
three
dimension
structur
conform
consequ
process
inactiv
virus
may
also
denatur
protein
protein
withstand
small
chang
conform
without
lose
biolog
activ
may
renatur
spontan
protein
lose
biolog
activ
minor
chang
conform
heat
use
inactiv
virus
protein
denatur
temperatur
protein
sharpli
defin
differ
protein
heat
definit
time
temperatur
denatur
temperatur
particular
protein
use
protein
purif
procedur
inactiv
virus
presenc
substrat
enzym
heat
temperatur
c
higher
absenc
substrat
explain
albumin
success
stabil
human
albumin
mani
bind
site
hydrophob
molecul
play
major
role
transport
fatti
acid
fill
site
stabil
acetyltryptophan
capryl
acid
fatti
acid
also
known
octano
acid
allow
albumin
withstand
heat
h
c
sinc
albumin
measur
biolog
activ
full
impact
heat
albumin
known
factor
viii
rapidli
inactiv
heat
solut
howev
dri
factor
viii
rel
heatstabl
certain
condit
observ
led
develop
heat
treat
factor
viii
prepar
fortun
hiv
nona
nonb
hepat
inactiv
heat
factor
viii
product
lower
biolog
activ
rel
insolubl
produc
higher
incid
factor
viii
inhibitor
moreov
hbv
complet
inactiv
heat
treatment
ivig
presenc
sugar
stabil
develop
one
ivig
stabil
ww
sorbitol
ph
heat
c
h
sever
envelop
virus
one
nonenvelop
viru
echo
viru
type
studi
virus
complet
inactiv
within
detect
limit
assay
system
use
log
reduct
echo
viru
substanti
chang
physicochem
biolog
properti
report
slight
increas
subclass
observ
anoth
ivig
heat
c
h
presenc
sucros
potassium
acet
stabil
envelop
virus
inactiv
detect
limit
within
h
heat
nonenvelop
encephalomyocard
viru
emcv
porcin
enteroviru
show
less
steadi
decreas
time
result
approxim
log
inactiv
h
c
howev
residu
infect
still
observ
complet
pasteur
process
thu
appear
heat
rel
effici
process
envelop
virus
effect
nonenvelop
virus
suscept
envelop
virus
elev
temperatur
may
explain
fact
heat
disintegr
lipid
bilay
convert
solid
liquid
reid
et
al
report
viru
inactiv
treat
ivig
low
level
pepsin
ph
envelop
virus
vaccinia
herp
simplex
hsv
mump
semliki
forest
viru
sfv
found
suscept
ph
treatment
polioviru
type
nonenvelop
acidst
viru
resist
author
also
observ
decreas
infect
vaccinia
hsv
ivig
sampl
incub
ph
without
pepsin
decreas
attribut
antibodi
mediat
neutral
similar
result
observ
kempf
et
al
studi
viru
inactiv
ivig
sampl
incub
ph
without
pepsin
hiv
hsv
type
cmv
vsv
sfv
inactiv
ph
incub
without
trace
amount
pepsin
inactiv
hsv
cmv
also
observ
ph
addit
experi
demonstr
addit
pepsin
ph
acceler
vsv
inactiv
evid
effect
low
ph
viru
inactiv
publish
louie
et
al
report
inactiv
bovin
viral
diarrhea
viru
bvdv
hcv
ivig
incub
ph
day
c
examin
bvdv
inactiv
condit
differ
ph
demonstr
increas
inactiv
decreas
ph
boschetti
et
al
recent
report
igg
solut
inactiv
ph
incub
c
minut
viru
mice
mvm
common
model
viru
stabl
condit
previous
observ
viru
inactiv
procedur
heat
solventdeterg
low
ph
inactiv
effect
envelop
virus
recent
evid
suggest
nonenvelop
virus
may
also
inactiv
therefor
viru
inactiv
low
ph
may
result
denatur
degrad
pepsin
present
membraneassoci
glycoprotein
envelop
virus
capsid
protein
nonenvelop
virus
presenc
lipid
envelop
bloodborn
virus
make
uniqu
suscept
inactiv
chemic
dissolv
dissoci
lipid
solvent
deterg
although
protein
also
denatur
solvent
deterg
expos
low
level
limit
period
time
without
signific
irrevers
effect
structur
function
observ
exploit
horowitz
cowork
develop
viru
inactiv
process
involv
addit
solvent
deterg
solventdeterg
treatment
first
appli
factor
viii
prepar
rapidli
replac
heat
treatment
standard
viru
inactiv
procedur
solventdeterg
viru
inactiv
soon
appli
wide
varieti
plasma
protein
consid
risk
transmit
virus
hepat
c
transmiss
ivig
report
solventdeterg
viru
inactiv
incorpor
sever
ivig
manufactur
process
use
procedur
requir
incub
period
reagent
remov
step
report
reduc
ivig
recoveri
lengthen
manufactur
time
also
consider
environment
burden
sinc
reduc
capac
ivig
product
ivig
manufactur
begin
abandon
solventdeterg
viru
inactiv
favour
process
filtrat
long
use
remov
bloodborn
pathogen
plasma
product
steril
germ
filtrat
mm
filter
remov
bacteria
fungi
process
effect
develop
filter
pore
size
small
enough
remov
virus
logic
consequ
develop
viru
remov
filter
protein
solut
handicap
need
process
larg
volum
reason
flow
rate
initi
problem
resolv
earli
viral
safeti
plasma
product
improv
implement
virusfiltr
process
scale
virusfiltr
simpl
robust
nondestruct
process
add
size
exclus
new
mechan
convent
viru
inactiv
partit
use
virusfiltr
remov
virus
first
major
advanc
viru
safeti
sinc
solventdeterg
treatment
introduc
sinc
discrimin
envelop
nonenvelop
virus
virusfiltr
potenti
remov
broadest
rang
pathogen
burnoufradosevich
et
al
report
excel
viru
remov
factor
ix
factor
xi
solut
use
planova
ashai
kasei
virusfilt
mean
pore
size
nanometr
nm
subsequ
new
virusfilt
introduc
manufactur
process
plasma
deriv
therapeut
studi
immunoglobulin
igg
solut
protein
concentr
mgml
ogradi
et
al
demonstr
planova
nm
filter
remov
log
mous
type
c
retroviru
sv
pseudorabi
viru
prv
wherea
polio
viru
remov
nm
filter
complet
elimin
iggsolut
planova
nm
filtrat
detect
limit
also
confirm
troccoli
et
al
virus
nm
mg
ml
igg
solut
mgml
igg
solut
addit
demonstr
excel
robust
planova
nm
deadend
virusfiltr
bvdv
iggsolut
regard
protein
salt
concentr
ph
pressur
temperatur
volum
per
filter
area
log
clearanc
virus
nm
hiv
bvdv
prv
also
found
van
holten
use
viresolv
millipor
filter
mgml
igg
solut
obtain
similar
result
ultipor
vf
grade
filter
pall
corpor
mgml
igg
solut
tabl
virusfiltr
becom
gener
accept
effici
robust
method
remov
virus
larger
pore
size
filter
howev
differ
observ
remov
studi
virus
size
smaller
pore
size
virusfilt
addit
pore
size
factor
composit
igg
solut
model
viru
use
probabl
import
factor
presenc
absenc
neutralis
crossreact
antibodi
may
play
role
elimin
capac
small
virus
studi
sever
author
planova
nm
filter
abl
elimin
log
emcv
log
hav
wherea
porcin
parvoviru
ppv
elimin
extent
log
two
planova
nm
filter
use
seri
use
viresolv
van
holton
demonstr
elimin
capac
log
emcv
log
hav
log
ppv
omar
kempf
specif
studi
effect
virusfiltr
remov
small
nonenvelop
virus
virus
studi
bovin
enteroviru
bev
nm
bovin
parvoviru
bpv
nm
minut
viru
mice
mvm
nm
virusfiltr
perform
ultipor
vf
grade
viru
remov
filter
filter
remov
log
bev
wherea
filter
remov
log
mvm
log
bpv
detect
limit
mgml
igg
solut
author
demonstr
remov
virus
diamet
smaller
virusfilt
pore
size
due
crossreact
human
antibodi
bound
virus
result
clearli
demonstr
signific
contribut
virusfiltr
make
overal
viral
safeti
ivig
product
transmiss
spongiform
encephalopathi
tse
degen
brain
diseas
transmit
inocul
ingest
nervou
system
tissu
diseas
subject
tse
diseas
includ
scrapi
sheep
bovin
spongiform
encephalopathi
bse
cattl
chronic
wast
diseas
cwd
deerelk
kuru
creutzfeldjacob
diseas
cjd
syndrom
gss
variant
cjd
vcjd
human
typic
diseas
symptom
human
form
dementia
progress
loss
brain
function
death
agent
respons
tse
transmiss
believ
compos
proteas
resist
protein
prp
call
prion
anim
studi
demonstr
infect
blood
transmiss
blood
infect
intracerebr
inject
experi
mouseadapt
strain
human
tse
demonstr
need
least
five
seven
time
infecti
agent
transmit
diseas
intraven
intracerebr
rout
mice
recent
studi
also
demonstr
bse
scrapi
transmit
sheep
intraven
inject
blood
experiment
infect
sheep
anoth
studi
primat
infect
bse
intraven
oral
rout
howev
evid
plasma
product
ever
transmit
cjd
vcjd
nevertheless
theoret
risk
transmiss
prompt
laboratori
studi
determin
behaviour
prion
plasma
fraction
tse
infect
mainli
elimin
igg
solut
two
mechan
partit
depth
filtrat
elimin
virusfiltr
effici
elimin
tse
infect
igg
solut
tabl
log
reduct
factor
model
virus
observ
laboratori
experi
ivig
product
carimun
nf
process
step
fig
author
report
log
reduct
factor
differ
tse
prepar
reduc
similar
extent
shown
tabl
consecut
step
addit
potenti
virusfiltr
reduc
tse
agent
investig
tateishi
et
al
albumin
solut
spike
scrapi
brain
homogen
significantli
reduc
remov
infect
observ
presenc
deterg
use
planova
nm
filter
log
versu
log
differ
remov
capac
observ
planova
nm
filter
effici
tse
remov
igg
solut
virusfiltr
demonstr
gregori
et
al
virusfiltr
ultipor
vf
grade
filter
reduc
tse
infect
log
see
tabl
date
ivig
therapeut
reach
high
safeti
standard
due
consequ
blood
plasma
test
introduct
viru
elimin
step
manufactur
process
tabl
show
lrf
obtain
manufactur
process
one
ivig
carimun
nf
follow
calcul
exampl
estim
risk
exposur
assum
pathogen
singl
dose
exampl
assum
manufactur
process
contain
three
independ
viru
elimin
mechan
eg
partit
inactiv
virusfiltr
also
assum
lower
detect
limit
lod
pool
nattest
current
hcv
geqml
hbv
geqml
hiv
geqml
set
highest
possibl
contamin
manufactur
pool
assumpt
risk
exposur
pathogen
singl
dose
calcul
use
follow
formula
sinc
singledon
minipool
test
taken
consider
calcul
may
consid
worstcas
scenario
result
show
low
risk
associ
administr
singl
dose
ivig
dedic
elimin
step
gener
suppos
reduc
viral
load
least
log
lrf
practic
larger
reduct
factor
may
result
viru
valid
studi
see
tabl
howev
valid
studi
effect
step
may
fulli
elucid
elimin
potenti
due
limit
titer
viru
spike
materi
detect
limit
assay
lead
minim
lrf
express
lrf
x
final
risk
transmit
pathogen
smaller
risk
exposur
contact
pathogen
necessarili
lead
infect
howev
sinc
exact
number
infect
effici
pathogen
vari
wide
depend
pathogen
host
health
assum
risk
transmiss
equal
risk
exposur
tragic
consequ
aid
epidem
emphas
import
incorpor
specif
pathogen
inactiv
remov
procedur
product
therapeut
protein
human
plasma
optim
procedur
elimin
known
pathogen
also
potenti
inactiv
remov
emerg
unknown
pathogen
may
infect
futur
blood
suppli
two
current
exampl
emerg
pathogen
caus
epidem
could
affect
blood
blood
product
epidem
sever
acut
respiratori
syndrom
sar
west
nile
viru
wnv
sar
corona
viru
sarscov
margin
threat
blood
product
safeti
diseas
progress
rapidli
howev
viremia
symptomat
patient
report
sar
epidem
produc
probabl
case
countri
case
fatal
rate
sarscov
repres
new
strain
human
coronaviru
coronavirus
envelop
rna
virus
rang
diamet
nm
roughli
spheric
inform
pathogenesi
sarscov
current
develop
difficult
predict
inactiv
remov
partit
sarscov
manufactur
ivig
data
avail
howev
remov
viru
use
virusfiltr
reason
assum
potenti
greater
concern
produc
human
plasma
protein
wnv
august
approxim
us
blood
donat
reactiv
wnv
nucleic
acid
test
wnv
spheric
nm
diamet
envelop
flaviviru
current
avail
data
strongli
suggest
wnv
unlik
transmit
plasma
tabl
elimin
hamster
scrapi
infect
manufactur
ivig
carimun
nf
process
step
fig
date
sever
commerci
ivig
produc
use
varieti
dedic
viru
elimin
procedur
procedur
categor
three
differ
elimin
mechan
attack
differ
physicochem
properti
pathogen
partit
step
classic
procedur
incorpor
ivig
manufactur
begin
low
ph
treatment
inactiv
step
incorpor
manufactur
ivig
make
intraven
toler
inactiv
procedur
specif
design
introduc
manufactur
process
elimin
virus
virusfiltr
simpl
robust
nondestruct
process
add
size
exclus
total
new
mechan
convent
viru
inactiv
partit
procedur
virusfiltr
potenti
elimin
emerg
virus
may
contamin
futur
blood
suppli
research
resist
emerg
pathogen
may
becom
relev
transmit
diseas
blood
product
futur
continu
